New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
10:21 EDTARRYArray BioPharma to present data at ASH meeting
Array BioPharma announced that data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2012 Annual Meeting of the American Society of Hematology. Array will also hold a conference call today at 4:30 p.m. ET, to review the abstracts. Early data from the ongoing combination with carfilzomib is reported in an abstract. In the ARRY-614 abstract, new formulation demonstrated improved bioavailability and inter-patient variability with in th ongoing study in low or intermediate-1 risk Myelodysplastic Syndromes, Array said. In its prior study in a similar population, the company said it observed a 38% response rate for hematologic improvement in patients receiving the highest dose of our prior formulation. At this dose, ARRY-614 demonstrated multilineage hematologic improvement in 67% of the responders, improving two or more cytopenia. Array intends to meet with the FDA to discuss the development plan to support registration.
News For ARRY From The Last 14 Days
Check below for free stories on ARRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
06:41 EDTARRYArray BioPharma shares attractive at current levels, says Piper Jaffray
Piper Jaffray says shares of Array BioPharma are attractive at current levels ahead of Phase III data readouts for binimetinib in melanoma, selumetinib in Kras-mutant lung, thyroid and uveal melanoma, and filanesib in multiple myeloma. Piper sees the biggest overhang on Array shares as being the financing requirement and it notes that binimetinib could be returned to the company from current partner Novartis (NVS). Nonetheless, it feels investors should take a "serious look" at Array and keeps an Overweight rating on the stock with a $9 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use